HIBio’s License Agreements with MorphoSys AG

Goodwin Procter advised HIBio on the deal while Orrick represented MorphoSys.

HIBio announced its equity participation agreement and license agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR). Under the agreements, HIBio is granted exclusive worldwide rights to develop and commercialize MorphoSys’ felzartamab, and MOR210, with the exception of Greater China for felzartamab and Greater China and South Korea for MOR210. MorphoSys will receive a 15% equity stake in HIBio and up to $1 billion in milestone payments across programs, plus single- to low double-digit royalties on net sales.

Human Immunology Biosciences (HIBio) is a biotechnology company focused on discovering and developing precision medicines for people suffering from autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph Capital.

MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases.

The Goodwin team was led by Sarah Stoiber, Laurie Burlingame (Picture) and Kingsley Taft, and included Amarilice Young, Ryan Donahoe and Gaebriella DeLisle. (Corporate), Simone Waterbury (Antitrust), Kevin Kabler and Pavel Puzerey (IP), Alex Varond (Regulatory) and Dan Karelitz (Tax).

The Orrick team advising MorphoSys was led by Thomas Schmid and David Ruff, and included Jay Schau and Jamie Kamen.

Involved fees earner: Laurie Burlingame – Goodwin Procter; Gaebriella DeLisle – Goodwin Procter; Ryan Donahoe – Goodwin Procter; Kevin Kabler – Goodwin Procter; Sarah Stoiber – Goodwin Procter; Kingsley Taft – Goodwin Procter; Alexander Varond – Goodwin Procter; Simone Waterbury – Goodwin Procter; Amarilice Young – Goodwin Procter; Jamie Kamen – Orrick Herrington & Sutcliffe LLP; David Ruff – Orrick Herrington & Sutcliffe LLP; Jay Schau – Orrick Herrington & Sutcliffe LLP; Thomas Schmid – Orrick Herrington & Sutcliffe LLP;

Law Firms: Goodwin Procter; Orrick Herrington & Sutcliffe LLP;

Clients: HIBio; MorphoSys AG;

Martina Bellini

Author: Martina Bellini